New platform features curated ecosystem of partners, enabling life science, healthcare and research professionals across enterprises to access innovative software and data offerings
LONDON, Sept. 9, 2020 /PRNewswire/ -- Clarivate Plc (NYSE: CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch of its online Innovation Exchange to enable life science, healthcare and research professionals to gain access to innovative software and data offerings from a curated ecosystem of approved partners. The carefully selected offerings enable clients to deliver timely and data-driven decisions as they seek to advance research, development and commercialization activities, enabled by rapid licensing and provisioning technologies.
The Innovation Exchange empowers relevant professionals by carefully matching their specific decision needs to an appropriate solution through an intuitive navigation tool and provides an increasing number of direct licensing options to facilitate rapid deployment within critical business environments. Certified applications will be delivered via the Clarivate Research Intelligence Cloud™ - providing an environment within which many industry leading collections of trusted, actionable insights can enable users across enterprises to access, synthesis and analyse critical data.
Gavin Coney, VP, Science Group Channels & Alliances at Clarivate, said: "The Clarivate Innovation Exchange is the transformation of our App Exchange concept, facilitating our relationships with world-class technology and data providers to deliver novel evidence-based capabilities to our global client base. With the unique visibility that we can bring to niche software and data innovators, and an expanded scope of novel tools, our customer response and levels of engagement have been extremely positive."
Collaborating with trusted partners, Clarivate will continue to combine extensive domain expertise with data science to deliver critical insights through harmonised cloud applications that empower customers to concentrate their efforts on development, reducing risk and launching new life-changing innovations - including new therapeutic interventions. Clarivate will continue to incorporate customer requests to identify and select future partners and expand the data processing capabilities of the Innovation Exchange platform.
The Innovation Exchange is launching with a suite of applications and data that support critical and common use cases including unique structure-activity datasets which offer rich insights into molecules and targets currently associated with dysfunctional immune response resulting from a hyperinflammatory cytokine storm seen in segments of the COVID-19 patient cohorts[1]. An example of mature analytics includes the Xplico drug valuation application – which incorporates decades of domain expertise and multiple data inputs to generate a robust valuation of any therapeutic asset.
To learn more about the Innovation Exchange, visit https://clarivate.com/innovation-exchange/
About Clarivate
Clarivate™ is a global leader in providing trusted information and insights to accelerate the pace of innovation. We offer subscription and technology-based solutions coupled with deep domain expertise that cover the entire lifecycle of innovation – from foundational research and ideas to protection and commercialization. Today, we're setting a trail-blazing course to help customers turn bold ideas into life-changing inventions. Our portfolio consists of some of the world's most trusted information brands, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. For more information please visit www.Clarivate.com.
Forward-Looking Statements
This press release and any statements included herein may contain forward-looking statements regarding Clarivate. Forward-looking statements provide current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of the control of Clarivate that may cause actual results to differ materially. Clarivate undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.
[1] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext
Logo - https://mma.prnasia.com/media2/1159266/clarivate_analytics.jpg?p=medium600
